Genmab: Janssen dispute cost DKK 146m in H1
Genmab's ongoing arbitration case with partner Janssen Pharmaceuticals has resulted in the latter withholding DKK 146m in royalty payments during the first half of 2021, the Danish biotech group informs.
BY ANDREAS LØNSTRUP, TRANSLATED BY DANIEL FRANK CHRISTENSEN
Even though Genmab's superseller, Darzalex, brought in USD 2.8bn in the first half of 2021 against USD 1.8bn from the same period last year – thereby playing a role in driving the recent guidance upgrade – the Danish biotech group is still able to note some less fortunate news for the period.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab's successful CEO dismisses retirement plans
For subscribers
Darzalex sales exceed expectations in second quarter
For subscribers
Janssen gets FDA approval for new Darzalex combination
For subscribers
.jpg&w=384&q=75)
